Tradestie Institutional Equity Comparison Engine
CRBP vs ANRO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ANRO Overall Edge
ANRO Captures Institutional Edge (3โ0 Pillars ยท 5โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Alto Neuroscience Inc. (ANRO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CRBP trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus ANRO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CRBP sits in BREAKDOWN (66th %ile IV; Dealer Gamma Walls on Pro) against ANRO sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
CRBP N/M vs ANRO N/M Fwd P/E
Growth & Margin Winner
ANRO
Op Margin 0.0% vs 0.0% ยท YoY -100.0% vs +0.0%
Momentum & Technical Winner
ANRO
1Y -69.5% vs +138.9% ยท 52W Pos 6% vs 61%
Options & Structure Winner
ANRO
BREAKDOWN (66th %ile IV) vs BREAKDOWN (8th %ile IV)
CRBP
NASDAQ
Corbus Pharmaceuticals Holdings, Inc.
Pharmaceutical Preparations
$3.38
-0.44% 1D
Market Cap
$69.9M
1M Return
-25.33%
1Y Return
-69.51%
Forward P/E
N/M
Unified AI Score
45.0 / 100
HOLD
Tech 43.0
Fund 54.0
Flow 69.0
Mom 64.0
ANRO
NYSE
Alto Neuroscience Inc.
Pharmaceutical Preparations
$27.12
-8.19% 1D
Market Cap
$1.2B
1M Return
+23.61%
1Y Return
+138.94%
Forward P/E
N/M
Unified AI Score
29.2 / 100
SELL
Tech 50.0
Fund 33.0
Flow 65.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CRBP -69.51%
ANRO +138.94%
Spread: +208.45 pp (ANRO Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CRBP TTM Op. Margin: 0.0%
ANRO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRBP vs ANRO. Trailing 12-month operating profitability (CRBP 0.0% vs ANRO 0.0%) and valuation multiples (CRBP N/M vs ANRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CRBP | ANRO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $69.9M | $1.2B | Larger Scale | ANRO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -100.0% | +0.0% | Higher Growth | ANRO |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -131.5% | -46.7% | Higher ROE | ANRO |
| 52-Week Range Position Momentum | 6% ($3โ$13) | 61% ($11โ$37) | Stronger Trend | ANRO |
| Beta / 30D Volatility Risk Regime | 1.93ฮฒ ยท 121% Vol | 1.95ฮฒ ยท 90% Vol | Lower Realized Risk | ANRO |
| Unified Institutional Score Composite Signal | 45.0 / 100 (HOLD) | 29.2 / 100 (SELL) | Higher Composite | CRBP |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CRBP vs ANRO Buy Guide
CRBP
BREAKDOWN
58d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
66th %ile
IV Regime
Elevated (60thโ80th %ile)
ANRO
BREAKDOWN
57d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
8th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CRBP nor ANRO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.